Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

What CDER Director Woodcock saw as a flexible and reasonable approach to approval of Sarepta's muscular dystrophy drug, ODE I Director Unger viewed as a threat to the substantial evidence standard.